其实在中,最常见的方案并不是rct,根据的阶段划分,可以分为探索性研究、培育性研究和验证性研究,三个阶段对方案证据强度的要求逐渐递增,而rct研究往往仅用于验证性研究中。反观一些基金,比如国自然,往往更倾向于支持涉及诊断、治疗、预后、病因等问题的探索性和培育性研究,因此在设计中,我们最常用到的其实还是观察性研究这一大类研究。无论您是队列研究、病例对照研究还是这些研究的衍生类别,其实都属于观察性研究。
本文介绍观察性研究的报告规范——strobe,供大家设计观察性研究方案的时候参考。与consort标准不同,strobe不仅针对一种研究方案,而是适用于队列、病例对照及其各种衍生研究设计方案,因此在storbe凯发天生赢家一触即发官网上,我们既能看到通用的清单,也有用于各类观察性研究的分清单。
strobe的全部信息和解读都可以从其官方网站(http://www.strobe-statement.org/)获取,目前最新版本的清单是2007年确定的第4版。在此我们同样把最新的strobe清单贴给大家参考,遗憾的是该清单并没有官方认可的中文翻译版。
strobe statement—checklist of items thatshould be included in reports of observational studies
no |
recommendation |
|
title and abstract |
1 |
(a) indicate the study’s design with a commonly used term in the title or the abstract |
(b) provide in the abstract an informative and balanced summary of what was done and what was found |
||
introduction |
||
background/rationale |
2 |
explain the scientific background and rationale for the investigation being reported |
objectives |
3 |
state specific objectives, including any prespecified hypotheses |
methods |
||
study design |
4 |
present key elements of study design early in the paper |
setting |
5 |
describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
participants |
6 |
(a) cohort study—give the eligibility criteria, and the sources and methods of selection of participants. describe methods of follow-up case-control study—give the eligibility criteria, and the sources and methods of case ascertainment and control selection. give the rationale for the choice of cases and controls cross-sectional study—give the eligibility criteria, and the sources and methods of selection of participants |
(b) cohort study—for matched studies, give matching criteria and number of exposed and unexposed case-control study—for matched studies, give matching criteria and the number of controls per case |
||
variables |
7 |
clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. give diagnostic criteria, if applicable |
data sources/ measurement |
8* |
for each variable of interest, give sources of data and details of methods of assessment (measurement). describe comparability of assessment methods if there is more than one group |
bias |
9 |
describe any efforts to address potential sources of bias |
study size |
10 |
explain how the study size was arrived at |
quantitative variables |
11 |
explain how quantitative variables were handled in the analyses. if applicable, describe which groupings were chosen and why |
statistical methods |
12 |
(a) describe all statistical methods, including those used to control for confounding |
(b) describe any methods used to examine subgroups and interactions |
||
(c) explain how missing data were addressed |
||
(d) cohort study—if applicable, explain how loss to follow-up was addressed case-control study—if applicable, explain how matching of cases and controls was addressed cross-sectional study—if applicable, describe analytical methods taking account of sampling strategy |
||
(e) describe any sensitivity analyses |
||
results |
||
participants |
13* |
(a) report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
(b) give reasons for non-participation at each stage |
||
(c) consider use of a flow diagram |
||
descriptive data |
14* |
(a) give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
(b) indicate number of participants with missing data for each variable of interest |
||
(c) cohort study—summarise follow-up time (eg, average and total amount) |
||
outcome data |
15* |
cohort study—report numbers of outcome events or summary measures over time |
case-control study—report numbers in each exposure category, or summary measures of exposure |
||
cross-sectional study—report numbers of outcome events or summary measures |
||
main results |
16 |
(a) give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). make clear which confounders were adjusted for and why they were included |
(b) report category boundaries when continuous variables were categorized |
||
(c) if relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |
||
other analyses |
17 |
report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |
discussion |
||
key results |
18 |
summarise key results with reference to study objectives |
limitations |
19 |
discuss limitations of the study, taking into account sources of potential bias or imprecision. discuss both direction and magnitude of any potential bias |
interpretation |
20 |
give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
generalisability |
21 |
discuss the generalisability (external validity) of the study results |
other information |
||
funding |
22 |
give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
*give information separately for cases and controls in case-controlstudies and, if applicable, for exposed and unexposed groups in cohort and cross-sectionalstudies.
note:an explanation and elaboration articlediscusses each checklist item and gives methodological background and publishedexamples of transparent reporting. the strobe checklist is best used inconjunction with this article (freely available on the web sites of plosmedicine at http://www.plosmedicine.org/, annals of internal medicine athttp://www.annals.org/, and epidemiology at http://www.epidem.com/).information on the strobe initiative is available at www.strobe-statement.org.
下一篇:临床研究中的诊断研究和筛检试验